You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

295 Results
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Aug 2020
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Funding:
New Drug Funding Program
    Durvalumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
Apr 2024
Drug
Other Name(s): Nubeqa®
Aug 2025
Guidelines and Advice
Status: Current
ID: ES 30-1
Mar 2021
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
Exceptional Access Program
    venetoclax - In Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia, based on criteria
Exceptional Access Program
    venetoclax - In Combination with Rituximab - Relapsed Chronic Lymphocytic Leukemia, based on criteria
Sep 2025
Drug
Other Name(s): Inqovi®
Feb 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Hairy Cell
Intent: Palliative
Mar 2022
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Jul 2022
Regimen
Cancer Type:
Head and Neck, 
Salivary Gland
Intent: Palliative
Jul 2022

Pages